ProCE Banner Events

Share

Transforming Precision NSCLC Care: Educating and Supporting Patients on HER2- and TROP2-Targeted ADCs

Expert discussions and takeaways for the evolving treatment landscape for HER2- and TROP2-targeted antibody–drug conjugates in NSCLC.

Physician Assistants : 2.00 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 2.00 Nursing contact hours, includes 2.00 hour of pharmacotherapy credit

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with NSCLC eligible for treatment with HER2- and TROP2-targeted ADCs.

Time and location

Friday, October 25, 2024

10:30 AM - 12:30 PM Central Time (CT)

Virtual

Agenda

Introduction and ARS Questions

Biology and Clinical Background of HER2/TROP2

  • Patient collaboration and education

Optimizing Biomarker Testing for HER2 in NSCLC

  • Patient education and available resources

Available/Emerging Clinical Data for HER2- and TROP2-Targeted ADCs in NSCLC

  • NCCN recommendations  
  • Latest clinical updates
  • Overview of other novel investigational agents in development for NSCLC
  • Strategies for improving health disparities in ROS1-positive NSCLC care

Closing Remarks and Question and Answer Session

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge and competence to optimize the treatment of NSCLC with HER2- and TROP2-targeted ADCs. 

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with NSCLC eligible for treatment with HER2- and TROP2-targeted ADCs. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Outline the role of HER2 and TROP-2 in NSCLC prognosis and treatment and key points for patient education in this area
  • Plan individualized treatment strategies for use of approved HER2-targeted ADC therapy in NSCLC, considering current evidence and guidelines, patient factors and preferences, and disease-related factors
  • Review current clinical trial evidence for targeting TROP-2 in patients with NSCLC with and without actionable genomic alterations
  • Assess patients for eligibility to enroll in clinical trials of combination strategies that include TROP2 or HER2-targeted ADCs in NSCLC
  • Apply communication strategies and recommended actions to identify and manage AEs and to increase patient awareness of potential ADC-related toxicities

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.